Summit Securities Group’s Sage Therapeutics SAGE Stock Holding History

Summit Securities Group’s Portfolio SAGE Stock Details SAGE Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q2	–	Sell	-127	Closed	-$1.01K	–	1389
2025 Q1	$1.01K	Buy	+127	New	+$930	﹤0.01%	700
2019 Q4	–	Sell	-5,800	Closed	-$714K	–	505
2019 Q3	$814K	Buy	+5,800	New	+$970K	0.07%	149

Other funds holding SAGE

MAP

Madison Avenue Partners New York $2.3B AUM 115.82% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Hudson Bay Capital Management Stamford, Connecticut $29B AUM 30.2% 1-Year Est. Return

D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return

Balyasny Asset Management Chicago, Illinois $77.1B AUM 42.89% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

AAM

Alpine Associates Management Palm Beach, Florida $1.7B AUM 97.55% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

6CM

683 Capital Management New York $1.92B AUM 85.52% 1-Year Est. Return

Summit Securities Group's SAGE Position: Q2 2025 in Review

Summit Securities Group sold out of Sage Therapeutics (SAGE) in Q2 2025, closing a stake of 127 shares — an estimated $1.01K sold.

Summit Securities Group first reported a position in SAGE in Q3 2019 and held it in 2 quarters. The position peaked at $814K in Q3 2019. 191 funds tracked by Wall St. Rank hold SAGE as of Q2 2025.

Summit Securities Group reported no remaining Sage Therapeutics position as of Q2 2025 after selling out during the quarter.
Summit Securities Group sold 127 Sage Therapeutics shares in Q2 2025, an estimated $1.01K.
Summit Securities Group first reported a position in Sage Therapeutics in Q3 2019 and held it in 2 quarters.
Summit Securities Group's Sage Therapeutics position peaked at $814K in Q3 2019.
191 funds tracked by Wall St. Rank held Sage Therapeutics as of Q2 2025.

Based on Summit Securities Group's 13F filing for Q2 2025, filed 12 Aug 2025.